All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Risk factors for hemorrhagic events in patients with polycythemia vera
Bookmark this article
|
Hemorrhagic events are a life-threatening complication that occur in 3–8% of patients with PV.1 A retrospective analysis assessed the association of clinical characteristics and hemorrhagic events in 267 patients with PV.1 Results from this analysis were published in Hematology by Furuya et al.1 |
| Key learnings |
| At a median follow-up of 4.8 years, post-diagnosis hemorrhagic events occurred in 8.6% of patients. There was a higher rate of hemorrhagic events in patients aged <60 years vs patients aged ≥60 years (16.7% vs 5.8%; p = 0.0012). |
| In the univariate analysis, WBC count ≥15.0 × 109/L (p = 0.002), palpable splenomegaly (p = 0.029), and JAK2V617F allele burden ≥80% (p = 0.003) were associated with hemorrhagic events among patients aged <60 years. |
| Multivariate analysis showed that JAK2V617F allele burden ≥80% in patients aged <60 years was associated with an increased risk of hemorrhagic events (HR, 9.394; 95% CI, 1.046–84.380; p = 0.046). |
| Results from this analysis identify potential risk factors for hemorrhagic events in younger patients with PV. Further studies are warranted to explore if therapies that reduce JAK2V617F allele burden may reduce the incidence of hemorrhagic events. |
Abbreviations: CI, confidence interval; HR, hazard ratio; PV, polycythemia vera; WBC, white blood cell.
- Furuya C, Hashimoto Y, Morishita S, et al. A higher JAK2 V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera. Hematology. 2024;29(1):2427905.
Related articles
Thrombotic and hemorrhagic complications in MPN
Thrombotic and hemorrhagic complications in MPN
Nov 30, 2023
Thrombotic and hemorrhagic complications in MPN
Thrombotic and hemorrhagic complications in MPN
Nov 30, 2023
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox